Systemic delivery of RNA-LPX vaccines carrying tumor-specific antigens (OVA for B16-OVA melanoma and gp70 for CT26 colon carcinoma), produced complete, long-lasting protection against subcutaneous tumor challenge, and re-challenge in the case of CT26. The gene discussed is EMB; the disease is neoplasm.